Literature DB >> 20091579

Corticosteroid regimens for treatment of acute and chronic graft versus host disease (GvHD) after allogenic stem cell transplantation.

Hojjat Salmasian1, Mersedeh Rohanizadegan, Setareh Banihosseini, Raheleh Rahimi Darabad, Mahtab Rabbani-Anari, Alia Shakiba, James L M Ferrara.   

Abstract

BACKGROUND: Corticosteroids are commonly used in treatment of acute and chronic graft-versus-host disease (GvHD). Nevertheless, there has been no systematic analysis of effects of their use on the patients' survival and quality of life.
OBJECTIVES: To compare the effect of corticosteroids in treatment of patients with GvHD and to compare the effect of different regimens of corticosteroids. SEARCH STRATEGY: We searched MEDLINE (up to July 2008), EMBASE (up to July 2008) and the Cochrane Controlled Trials Register (up to July 2008) to identify relevant studies. All of the references were assessed in order to identify additional trials. SELECTION CRITERIA: Randomized controlled trials of any language were included in the study as long as they met any of the predefined comparisons of interest. The primary outcome in question was the overall survival of the patients. Due to lack of evidence, inclusion criteria was revised during the process of the review to include studies comparing different dosage of corticosteroids. DATA COLLECTION AND ANALYSIS: All derived citations and abstracts were screened by two independent review authors for relevance. For the potentially relevant trials, the full text was obtained and reviewed by two review authors independently. Two review authors completed data extraction independently. After revising the inclusion criteria, this process was retried to ensure all relevant evidence is included in the review. MAIN
RESULTS: No studies met the original inclusion criteria but two studies (four articles) met the revised inclusion criteria. As they addressed different clinical questions, meta-analysis was not performed. The outcomes of one study were in favor of efficacy of corticosteroids in inducing an earlier remission of acute GvHD, while the other study reported that early corticosteroid therapy of acute GvHD could not prevent progression of the disease to higher grades, although it was accompanied by a slightly better prognosis in the patients who responded by the fifth day of treatment. AUTHORS'
CONCLUSIONS: There is no certain study regarding appropriate use, dose and length of therapy for acute GvHD. Further studies are needed to define the appropriate use of steroids and whether other agents are appropriate as frontline therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20091579      PMCID: PMC7388928          DOI: 10.1002/14651858.CD005565.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  24 in total

Review 1.  Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses.

Authors:  D Moher; D J Cook; A R Jadad; P Tugwell; M Moher; A Jones; B Pham; T P Klassen
Journal:  Health Technol Assess       Date:  1999       Impact factor: 4.014

2.  Corticosteroids in the prevention of graft-vs-host disease after allogeneic myeloablative stem cell transplantation: a systematic review and meta-analysis.

Authors:  S Quellmann; G Schwarzer; K Hübel; A Engert; J Bohlius
Journal:  Leukemia       Date:  2008-05-01       Impact factor: 11.528

Review 3.  Chronic graft-versus-host disease: is there an alternative to the conventional treatment?

Authors:  D Gaziev; M Galimberti; G Lucarelli; P Polchi
Journal:  Bone Marrow Transplant       Date:  2000-04       Impact factor: 5.483

4.  Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial.

Authors:  F Locatelli; B Bruno; M Zecca; M T Van-Lint; S McCann; W Arcese; S Dallorso; P Di Bartolomeo; F Fagioli; A Locasciulli; M Lawler; A Bacigalupo
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

5.  Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process.

Authors:  Benny J Chen; Xiuyu Cui; Congxiao Liu; Nelson J Chao
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

6.  Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone.

Authors:  H J Deeg; T P Loughran; R Storb; M S Kennedy; K M Sullivan; K Doney; F R Appelbaum; E D Thomas
Journal:  Transplantation       Date:  1985-08       Impact factor: 4.939

7.  Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial.

Authors:  I M Hings; A H Filipovich; W J Miller; B L Blazar; P B McGlave; N K Ramsay; J H Kersey; D J Weisdorf
Journal:  Transplantation       Date:  1993-09       Impact factor: 4.939

8.  Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.

Authors:  R Srinivasan; S Chakrabarti; T Walsh; T Igarashi; Y Takahashi; D Kleiner; T Donohue; R Shalabi; C Carvallo; A J Barrett; N Geller; R Childs
Journal:  Br J Haematol       Date:  2004-03       Impact factor: 6.998

Review 9.  Management of acute graft-versus-host disease.

Authors:  Andrea Bacigalupo
Journal:  Br J Haematol       Date:  2007-04       Impact factor: 6.998

10.  High dose bolus methylprednisolone for the treatment of acute graft versus host disease.

Authors:  A Bacigalupo; M T van Lint; F Frassoni; M Podesta'; G Veneziano; G Avanzi; V Vitale; A M Marmont
Journal:  Blut       Date:  1983-03
View more
  9 in total

1.  Efficacy of PTX3 in a rat model of invasive aspergillosis.

Authors:  Pietro Lo Giudice; Silvia Campo; Antonio Verdoliva; Vincenzo Rivieccio; Franco Borsini; Rita De Santis; Giovanni Salvatori
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

Review 2.  Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in children and adolescents.

Authors:  Kathrin Buder; Matthias Zirngibl; Sascha Bapistella; Joerg J Meerpohl; Brigitte Strahm; Dirk Bassler; Marcus Weitz
Journal:  Cochrane Database Syst Rev       Date:  2022-09-27

Review 3.  Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in children and adolescents.

Authors:  Kathrin Buder; Matthias Zirngibl; Sascha Bapistella; Joerg J Meerpohl; Brigitte Strahm; Dirk Bassler; Marcus Weitz
Journal:  Cochrane Database Syst Rev       Date:  2022-06-09

4.  Relationship between corticosteroid dose and declines in physical function among allogeneic hematopoietic stem cell transplantation patients.

Authors:  Shinichiro Morishita; Katsuji Kaida; Shinya Yamauchi; Koichiro Sota; Shinichi Ishii; Kazuhiro Ikegame; Norihiko Kodama; Hiroyasu Ogawa; Kazuhisa Domen
Journal:  Support Care Cancer       Date:  2013-03-09       Impact factor: 3.359

Review 5.  Graft-versus-host disease affecting oral cavity. A review.

Authors:  Maria Margaix-Muñoz; José V Bagán; Yolanda Jiménez; María-Gracia Sarrión; Rafael Poveda-Roda
Journal:  J Clin Exp Dent       Date:  2015-02-01

6.  Comparison of the Efficacy of Topical Triamcinolone in Orabase and Curcumin in Orabase in Oral Graft-Versus-Host Disease.

Authors:  Arash Mansourian; Babak Bahar; Mahdieh Sadat Moosavi; Massoud Amanlou; Shahabodin Babaeifard
Journal:  J Dent (Tehran)       Date:  2017-11

Review 7.  Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients.

Authors:  Marcus Weitz; Brigitte Strahm; Joerg J Meerpohl; Maria Schmidt; Dirk Bassler
Journal:  Cochrane Database Syst Rev       Date:  2015-12-15

8.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report.

Authors:  Zachariah DeFilipp; Daniel R Couriel; Aleksandr Lazaryan; Vijaya Raj Bhatt; Nataliya P Buxbaum; Amin M Alousi; Attilio Olivieri; Drazen Pulanic; Joerg P Halter; Lori A Henderson; Robert Zeiser; Ted A Gooley; Kelli P A MacDonald; Daniel Wolff; Kirk R Schultz; Sophie Paczesny; Yoshihiro Inamoto; Corey S Cutler; Carrie L Kitko; Joseph A Pidala; Stephanie J Lee; Gerard Socie; Stefanie Sarantopoulos; Steven Z Pavletic; Paul J Martin; Bruce R Blazar; Hildegard T Greinix
Journal:  Transplant Cell Ther       Date:  2021-06-11

Review 9.  Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients.

Authors:  Marcus Weitz; Brigitte Strahm; Joerg J Meerpohl; Maria Schmidt; Dirk Bassler
Journal:  Cochrane Database Syst Rev       Date:  2015-12-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.